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Reversible protein phosphorylation is a central regulatory mechanism of cell function. Deregula- 
tion of the balanced actions of protein kinases and phosphatases has been frequently associated 
with several pathological conditions, including cancer. Many studies have already addressed the 
role of protein kinases misregulation in cancer. However, much less is known about protein phos- 
phatases influence. Phosphoprotein Phosphatase 1 (PPP1) is one of the major serine/threonine 
protein phosphatases who has three catalytic isoforms: PPP1CA, PPP1CB, and PPP1CC. Its function 
is achieved by binding to regulatory subunits, known as PPP1-interacting proteins (PIPs), which 
may prefer a catalytic isoform. Also, some inhibitors/enhancers may exhibit isoform specificity. 
Here we show that, prodigiosin (PG), a molecule with anticancer properties, promotes the forma- 
tion of PPP1CA-AKT complex and not of PPP1CC-MAPK complex. Both, AKT and MAPK, are well- 
known PIPs from two pathways that crosstalk and regulate melanoma cells survival. In addition, 
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interacts with obatoclax (OBX), a drug that belongs to the same family of PG. Overall, these results 
suggest that PG might, at least in part, act through PPP1C/PIPs. Also, this study is pioneer in de- 
monstrating PPP1 isoform-specific modulation by small molecules. 
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Reversible phosphorylation of proteins is a major intracellular regulatory mechanism in eukaryotes, resulting 
from the dynamic and coordinated action of protein kinases and phosphatases [1]. This post-translational modi- 
fication has been associated with many cell signaling pathways which, in turn, regulate several cellular events [2] 
[3]. So, unsurprisingly, some of the most prevalent pathological conditions (e.g. cancer, diabetes, and neurode- 
generative conditions) are, at least in part, consequence of the abnormal phosphorylation of key proteins [4]. 
Phosphoprotein Phosphatase 1 (PPP1), one of the most important serine/threonine phosphatases, has been re- 
ceiving increasing attention. PPP1 actions are dependent on the interaction of its catalytic subunit (PPP1C) with 
regulatory subunits, known as PPP1-interacting proteins (PIPs). Hence, besides the PPP1 role in cell cycle pro- 
gression [5] [6] and apoptosis [7] [8], two cellular events that when dysfunctional induce tumorigenesis, it also 
interacts directly with proteins involved in specific types of cancer, such as BRAC1 (breast cancer) [9], AKT 
and MAPK (melanoma, colon cancer, etc.) [10]-[14]. These interactions suggest that PPP1C/PIPs complexes are 
potential targets for anticancer therapy. 
Compounds that directly interfere with PPP1Chave been exploited as anticancer drugs, not only as single 
agents but also in combination with conventional treatments. Several naturally occurring toxins, as cantharidin 
(CT) and its analogues, have been extensively studied but they still have many drawbacks, including severe toxic 
side effects [15] [16]. Alternatively, the targeting of PPP1C/PIP complexes has been demonstrated as a remark- 
able strategy, as PIPs are more event, tissue, and subcellular compartment specific [4]. For example, treatment 
of glioblastoma and prostate cancer cells with the histone deacetylases (HDACs) inhibitor, trichostatin A (TSA), 
disrupts the PPP1C/HDAC6 complex, resulting in increased dephosphorylation or acetylation of, for example, 
AKT, thus decreasing its activity [17]. Also, the formation of the PPP1-GADD34 complex is decreased in cells 
treated with salubrinal, a small molecule that protects the cell from ER-stress-induced apoptosis. 
A number of interesting anticancer properties have also been described for a few prodiginine family members, 
with prodigiosin (PG) and obatoclax (OBX) being two of the most prominentones. Previous studies have dem- 
onstrated that PG proapoptotic effect in breast cancer cells is mediated by induction of the gene NAG-1. This 
occurs via glycogen synthase kinase-3β (GSK3β) activity, a downstream substrate of both PI3K/AKT and 
MAPK pathways, which are strongly regulated by PPP1C [18]. On the other hand, OBX was described as a BH3 
mimetic, targeting several anti-apoptotic Bcl-2 family members [19] that are already known PIPs [8]. However, 
its mechanism of action remains poorly understood. More recently, few additional protein kinases were identi- 
fied as being negatively regulated by PG. Interestingly, all of them participate in PI3K/AKT/mTOR and MAPK 
pathways. The inhibition of such kinases, mainly mTORC1 and mTORC2 complexes, culminates in the loss of 
AKT phosphorylation at S473 [20]. 
In order to evaluate the role of PPP1C in prodiginines-mediated effect in tumorigenesis, we analyzed the ac- 
tion of PG in human melanoma cell lines subjected to a PPP1C inhibition treatment. Moreover, to assess PPP1C 
as a potential molecular target of prodiginines, we performed a real-time interaction analysis using Surface 
Plasmon Resonance (SPR) technology. 
2. Material and Methods 
2.1. Drugs and Reagents 
PG (2-methyl-3-pentyl-6-methoxyprodigiosene) was provided by Dr. R. J. Schultz of the National Cancer Drug 
Synthesis and Chemistry Branch Chemotherapeutic Agents Repository (Bethesda, MD). OBX, a synthetic indol- 
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containing prodiginine, was provided by Dr. Roberto Quesada of the University of Burgos. CT was purchased 
from Sigma-Aldrich (Sintra, Portugal). All stock solutions were diluted in DMSO and stored at −20˚C. 
2.2. Cell Lines and Culture Conditions 
Human melanoma cells SK-MEL-5 were purchased from American Type Culture Collection (Barcelona, Spain). 
Cells were cultured in Minimum Essential Medium (MEM, Gibco, Madrid, Spain) containing GlutaMAX, sup- 
plemented with 5% fetal bovine serum (FBS, Gibco, Madrid, Spain), 1% L-glutamine, 10 mg/ml antibiotic and 
antimycotic mixture (Gibco, Madrid, Spain) and non-essential amino acids, and grown in a 5% CO2 humidified 
incubator at 37˚C. 
2.3. Western Blot Analysis 
Briefly, cells were treated with 10 µMCT and 0.15 µM or 0.38 µM PG for 30 or 60 minutes (details ofthe dura- 
tion of the treatments are provided on each figure). Cells were then harvested in 1% sodium dodecyl sulfate 
(SDS) and the protein content of the cell lysates was determined by the bicinchoninic acid method (BCA) 
(Pierce, Rockford, IL, USA) using bovine serum albumin as standard. Mass-normalized samples were loaded 
onto SDS-PAGE and subsequently transferred onto nitrocellulose membranes (GE Healthcare, Carnaxide, Por- 
tugal). Immunoblotting of the transferred proteins was performed as previously described [21] and immunoreac- 
tive bands were revealed by incubation with a HRP-conjugated secondary antibody followed by ECL detection 
(Amersham Pharmacia, Piscataway, USA). All the experiments were repeated at least three times. 
2.4. Antibodies 
Anti-PPP1CA antibody (CBC2C, dilution 1:2500) and anti-PPP1CC antibody (CBC3C, dilution 1:5000), 
against the C-terminus of the proteins, are homemade rabbit polyclonal antibodies from the Centre for Cell Bi- 
ology (University of Aveiro, Portugal) [22]. Anti-AKT (cat. 9272S, dilution 1:1000), anti-phospho AKT (S473) 
(cat. 9271S, dilution 1:1000) and anti-phospho GSK3α/β (S21/9) (cat. 9331S), all raised in rabbit, were pur- 
chased from Cell Signalling (Massachusetts, USA). Mouse anti-MAPK antibody (cat. 612280, dilution 1:1000) 
was acquired from BD Biosciences (Madrid, Spain), and rabbit anti-phospho MAPK (Thr202/Tyr204) (dilution 
1:1000) antibody was obtained from Santa Cruz Biotechnology, Inc. (Heidelberg, Germany). Monoclonal anti- 
PARP antibody and anti-β tubulin (dilution 1:1000), both raised in mouse, were purchased from Zymed Labora- 
tories, Inc. (Cambridge, UK). Goat anti-actin antibody (cat. sc-1616) was obtained from Santa Cruz Biotech- 
nology, Inc. (Heidelberg, Germany), and mouse anti-vinculinantibody (cat. V9131) from Sigma-Aldrich (Sintra, 
Portugal). 
2.5. Surface Plasmon Resonance Assays 
Surface plasmon resonance (SPR) was performed using Biacore T100, which takes advantage of SPR detection 
at gold surfaces and reagent handling in a microfluidic system. This sensitive and high-performance system en- 
able monitoring in real time, using label-free assay formats, the interaction between biomolecules. PPP1CA 
(New England BioLabs, Hitchin, UK) was covalently attached to a CM5 sensor chip according to amine coupl- 
ing protocol. Activation of the surface with 1-ethyl-3 (3-dimethylaminopropyl) carbodiimide (EDC) and N-hydro- 
xysuccinimide (NHS) was followed by injection ofPPP1CA protein; the excess of reactive groups were deacti- 
vated with ethanolamine. PPP1CA was diluted to 1 ng/µl in acetate buffer pH 4.8, and immobilized to a level of 
3982 response units (RU). All the assays were carried out at 25˚C using HBSN buffer (10 mM Hepes and 150 
mM NaCl, pH 7.4) supplemented with 100 mM MgCl2. The same buffer was used to dilute OBX. OBX was in- 
jected over sensor surfaces for 60s at 30 µl/min. The complexes were regenerated back using 25 mM NaOH. 
The same protocol was followed for PPP1CC, a homemade purified protein, except for the running buffer whose 
constitution was previously described in Stenlund, P. et al. [23]. 
3. Results 
3.1. Prodigisin and Cantharidin Treatment Have Opposite Effects Onphosphorylated  
AKT in Melanoma Cells 
In a first step, we aimed to determine the involvement of PPP1 in the reversible phosphorylation system that re- 
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gulates the AKT signaling pathway. For this, we determined the expression levels of phosphorylated AKT 
(pAKT, S463) in human melanoma cells treated with PG or CT. SK-MEL-5 cells, derived from axillary node 
metastasis were treated with 1 µM PG (corresponding to the IC50 at 24 hours [20]) or 10 µM CT (a concentra- 
tion that inhibits PPP1 [24]) for 30 and 60 minutes. Treatment with PG decreased pAKT expression levels by 60% 
after 30 minutes and by 80% after 60 minutes treatment, which is in accordance with previous studies [20]. By 
contrast, CT treatment increased pAKT by 60% after 30 minutes, with levels returning to near the baseline after 
60 minutes (Figure 1). 
3.2. PPP1 Binds Prodiginines Family Members 
Taking into account the previous results, we hypothesized that PG could be acting through PPP1. Thus, we used 
a real-time interaction approach, based on SPR technology, to address the ability of prodiginines family mem- 
bers to bind PPP1. This technique was previously applied to characterize the binding of prodiginines to mTOR 
[20]. 
Binding experiments were initiated by immobilizing purified recombinant proteins PPP1CA or PPP1CC on a 
sensor surface. Then, the analytes (PG and OBX) were injected in solution over the surface and the interactions 
were analyzed, providing kinetics and affinity data in the nanomolar range. Due to technical constrains, includ- 
ing PG precipitation in the buffer used, we were not allowed to achieve accurate conclusions about PPP1CA/CC 
interaction with PG. On the other hand, predicted affinity and kinetic constants showed that OBX binded to the 
tested isoform, PPP1CA, with a calculated KD in a range of nanomolar (1.8E−10 ± 1.1E−10 M). The KD ob- 
tained indicates a high affinity interaction. Moreover, the disassociation constant Kd (0.017 s-1) indicates that 
OBX binds to PPP1CA, forming a stable complex (Figure 2). 
In what concerns PPP1CC, we performed the experiments according to Stenlund, P. et al. [25], but we used 
calyculin A instead of okadaic acid in the coupling buffer. However, results were not as consistent as for 
PPP1CA, showing only a minorbind capability for OBX, along with a low specificity interaction (data not 
shown). 
3.3. Cantharidin and Prodigiosin Actions on PPP1C Areisoform-Specific 
To address the effects of PG and CT on PPP1CA and PPP1CC, we performed a sequential treatment on cultured 
cells. SK-MEL-5 cells were pre-incubated for 30 minutes with 10 µM CT followed by incubation with 0.15 µM 
and 0.38 µM PG (corresponding to the IC12.5 and IC25 at 24 hours, respectively) for 30 minutes or 60 minutes. 
The expression levels of both isoforms were then assessed (Figure 3(a) and Figure 3(b)). 
To assure that the observed effect was exclusively the result of the action of the drugs and not because of cell 
death we analyzed apoptosis using the advanced apoptosis marker PARP. For that, we evaluated the ratio of 
cleaved PARP/total PARP (Figure 3(c)). 
PPP1CA and PPP1CC did not exhibited similar responses to PG treatment preceded by CT treatment. A 
treatment of 0.15 µM PG for 30 minutes decreased PPP1CA levels by 25%, while increased PPP1CC levels in 
80%. After this initial increase, PPP1CC levels decreased along with the augment of PG concentration and in- 
cubation time. On the other hand, the decrease in PPP1CA levels remained observable followed by a 60 minutes 
PG treatment, but when treated with 1 µM PG PPP1CA levels increased. 
3.4. PPP1CA and PPP1CC Act on Different Signaling Pathways in Response to Prodigiosin: 
AKT and MAPK Pathways 
The explanation for the different responses of PPP1 isoforms to PG treatment, in human melanoma cells, may 
lie on distinct downstream effects on particular genes, which are targets of relevant signaling proteins. As AKT 
phosphorylation is affected by PG treatment, we analyzed changes on AKT and MAPK pathways in response 
tothe referred treatment, and addressed if the results correlate with PPP1CA and PPP1CC expression levels. 
Interestingly, the ratio pAKT/AKT varied inversely to PPP1CA levels (Figure 3(a) and Figure 4(a)), whe- 
reas MAPK/pMAPK changed in accordance to PPP1CC levels (Figure 3(b) and Figure 4(b)). After 30 minutes 
of PG treatment, PPP1CCachieved its highest expression level, corresponding to the lowest level of 
pMAPK/MAPK, with the opposite being observed after 60 minutes of PG treatment. In addition, the expression 
pattern of GSK3, a common substrate of AKT and MAPK, and its phosphorylated form, pGSK3, were analyzed 




Figure 1. Expression of phosphorylated v-Akt murine 
thymoma viral oncogene(pAKT)in SK-MEL-5 cells treat- 
ed with prodigiosin (PG) or cantharidin (CT). Cells were 
treated with 1 µM PG or 10 μM CT and cell extracts 
were assayed for pAKT expression by immunoblot- 
ting. Actin and vinculin were used as loading controls. 
Experiments were repeated at least twice.             
 
 
Figure 2. Kinetic and affinity characterization of obatoclax binding to phosphoprotein phosphatase 1 isoform α (PPP1CA) 
by surface plasmon resonance assay. Obatoclax (OBX) was injected, at a range of concentrations between 0.04 nM and 2.5 
nM, over the immobilized PPP1CA. Sensograms and curve fits (smooth lines), assuming 1:1 interactions, are depicted in 
panel (a) and (b). Reference and blank data were subtracted. The similar dissociation rates (KD) on both kinetic and affinity 
sensograms (panel (c)) confirms the specificity of the binding.Experiments were repeated at least twice.                    
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(a)                                           (b) 
 
(c) 
Figure 3. Phosphoprotein phosphatase 1 isoforms α and γ (PPP1CA and PPP1CC, respec- 
tively) have different responses to prodigiosin (PG) treatment in human melanoma cells. 
SK-MEL-5 cells were treated with 10 μM cantharidin (CT) for 30 minutes and then were 
incubated with 0.15 µM or 0.38 µM PG for 30 minutes (2 and 4) or 60 minutes (3 and 5). As 
control (1), cells were incubated for 90 minutes with 10 μM CT. Cell extracts were assayed for 
PPP1CA (a) and PPP1CC (b) expression by immunoblotting. Apoptosis was assed using total 
poly ADP ribose polymerase (PARP) and cleaved PARP (cPARP). Tubulin was used as load- 
ing control. Experiments were repeated at least twice.                                   
 
    
(a)                                              (b) 
 
(c) 
Figure 4. Phosphoprotein phosphatase 1 isoforms α and γ (PPP1CA and PPP1CC, respectively) act on kinases 
from different signaling pathways. Cells were treated with 10 μM cantharidin (CT) for 30 minutes, after which 
were incubated with 0.15 µM or 0.38 µM prodigiosin (PG) for 30 minutes (2 and 4) or 60 minutes (3 and 5). 
As control (1), cells were incubated for 90 minutes with 10 μM CT. Cell extracts were assayed by im- 
munoblotting for v-Akt murine thymoma viral oncogene (AKT) and phosphorylated AKT (pAKT) (a), 
mitogen-activated protein kinase (MAPK) and phosphorylated MAPK (pMAPK) (b), and glycogen synthase 
kinase-3 beta (GSK3) (c). Tubulin was used as loading control. Experiments were repeated at least twice.      
 
under the same conditions (Figure 4(c)). Results show that pGSK3 expression levels decreased along with the 
decreased of pMAPK (the active form). 
4. Discussion 
Reversible protein phosphorylation is an essential post-translational modification that regulates numerous cellu- 
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lar processes. The impairment of the correct balance between protein kinases and phosphatases leads to the onset 
and progression of several pathological conditions, including cancer [6]. 
Protein kinases have been shown to be dysfunctional in many types of cancer; therefore, kinase inhibitors 
have been largely explored for therapeutic purposes [26] [27]. Protein phosphatases, on the other hand, remain 
poorly understood but have been receiving increasing attention. PPP1C, a major serine/threonine phosphatase 
whose activity is dependent on the partners it binds to, has been extensively studied as a target for pharmaco- 
logical intervention. A treatment used in glioblastoma and in prostate cancer cells targets the complex PPP1C/ 
HDAC6, which induces the dephosphorylation of pAKT—component of a signaling pathway that, when acti- 
vated, induces cell proliferation and survival [28]. Previous work from Xiao, L., et al. and Thayyullathil, F., et al. 
showed that PPP1C could bind pAKT, being responsible for its dephosphorylation at T450 and S473 residues 
[11] [12]. On the other hand, work from Soto-Cerrato, V., et al. stated that PG, a molecule with anticancer prop- 
erties, also promotes the dephosphorylation of pAKT [18]. These assumptions led us to hypothesize that PG 
could be acting, at least in part, through PPP1C/PIPs complexes. 
Here, we addressed the effect of PPP1 Cinhibition in the expression levels of pAKT (S473), using human me- 
lanoma cells where the AKT pathway has been shown to be hyperactivated [29]. Indeed, the levels of pAKT 
(S473) increased after 30 minutes of CT treatment and decreased in response to PG treatment as expected 
(Figure 1). This indicates that AKT dephosphorylation, might be, at least in part, accomplished by PPP1, as al-
ready observed in other studies [30]. The mechanism by which PG leads to the dephosphorylation of AKT, non-
etheless, remains unknown. 
In a next step, to analyze the binding ability of PG to PPP1C, we first performed an in vitro binding assay us- 
ing SPR. Unfortunately, PG precipitated very easily during the experimental procedure and OBX (an analogue 
from the same family) was used instead. Overall, SPR analysis results suggest that PPP1 is one of the targets of 
prodiginines, but isoforms exhibit distinct affinities for the drug. Affinity and kinetics evaluation of the interac- 
tion confirmed the specificity and high affinity of the bindingtoPPP1CA (Figure 2(a) and Figure 2(b)). Pre- 
viously, a similar assay was performed to test the binding between PPP1CCA and two PPP1C inhibitors (CT 
and okadaic acid) [23]. Although the immobilization conditions and buffers were different, we can draw some 
putative interesting conclusions that, nevertheless, have to be proved in a near future. The Kd for PPP1CA/OBX 
binding was higher (Figure 2(c)) than for PPP1CA/CT, thus OBX could hypothetically displace CT from 
PPP1C. However, PPP1CA/CT binding appears to be more stable because the Kd is lower [23]. 
After demonstrating that PPP1CA can bind to a prodiginine family member and knowing that PPP1C inhibi- 
tion enhances the phosphorylation of AKT [31], efforts were made to understand the relationship between PPP1C 
and PG, and their modulatory potential on relevant signaling pathways in human melanoma cells. 
The CT pre-treatment for 30 minutes, as suggested by our results (Figure 3) and by others [24], should inhibit 
PPP1C but not change significantly its amounts. Hence, the variation in the expression levels of PPP1C must be 
due to the presence of PG. Interestingly, the alterations induced on the PPP1C isoforms analyzed were different, 
suggesting a distinct mode of action of PG on PPP1CA and PPP1CC.There is no literature concerning PPP1 
isoforms-specific inhibition or enhancement by small molecules, so this data unlocks very interesting issues. 
PG seems to displace CT from PPP1C (Figure 3) and, somehow, alters the amount of PPP1 within the cells. 
The duration of the treatment was too short to induce significant changes in protein expression at the mRNA 
level; therefore, the explanation may lie in the alteration of protein degradation processes and consequent pro- 
motion of the targeting of PPP1CA to degradation. In contrast, PPP1CC peaked after 30 minutes of 0.15 µMPG 
treatment (Figure 3(b)), which may correspond to a compensatory effect resulting, for example, from PPP1CC 
mRNA local translation [32], and that could be bypassed through increasing the concentrations of PG or the 
time of incubation. 
Another remarkable observation was that the expression pattern of PPP1CAcorrelated with the expression 
pattern of AKT (Figure 4(a)), but the same was verified for PPP1CC. For this reason, we progressed for the 
study of another kinase that could be a preferential target for PPP1CC. MAPK signaling pathway, which 
cross-talks with the AKT signaling pathway and is inhibited when the latter one is active, have also been re- 
ported as being altered in melanoma [13]. Surprisingly, the phosphorylation of MAPK (Figure 4(b)) increased 
when the expression levels of PPP1CCwere reduced. After 30 minutes of 0.15 µM and 0.38 µMPG treatment 
the decrease in pMAPK phosphorylation was of 40% and 90%, respectively. However, this decrease was not 
proportional to the increase in PPP1CCexpression levels, as the increase was of 80% (0.15 µM) and 20% (0.38 
µM). So, we hypothesized that another kinase might also be involved. In a next step we assessed GSK3 expres- 
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sion levels (Figure 4(c)), a common substrate of both AKT and MAPK, and the results suggest that it is under 
the regulation of MAPK in the conditions of the experiment. All together, the results suggest that PPP1CA spe- 
cifically dephosphorylates pAKT, while pMAPK is a preferential target for PPP1CC. Also, in the conditions of 
the experiments, MAPK appears to be the major kinase responsible for inactivating GSK3 by phosphorylation. 
5. Conclusions 
The identification of putative targets for pharmacological interference, mainly signaling molecules, has been in- 
teresting the research community and also pharmaceutical companies for the last decade. Recently, protein 
phosphatases have become also prime focus of attention, in particularPPP1/PIP complexes due to their specific- 
ity [28]. In what concerns cancer, several components of signaling pathways have shown to be deregulated and, 
apart from that, more than one pathway may contribute to carcinogenesis. 
In melanoma, several studies have been pointing out the cross-talk between MAPK and AKT signaling path- 
ways [13]. For instance, B-RAF activity increases after treatment with an AKT inhibitor [33] [34]. Interactions 
between different signaling pathways can regulate drugs mode of action, turning them more or less effective or 
promoting drug resistance. Several studies have shown that the cross-talk between AKT and MAPK pathways 
can be used more efficiently to treat melanoma by inhibiting AKT, thus promoting apoptosis and activating RAF 
to induce senescence [13]. 
Here we show that PPP1CA preferentially binds AKT, whereasPPP1CC preferential targets MAPK. In the 
presence of PG, PPP1CC will be targeted to degradation, increasing the phosphorylation of both MAPK and 
GSK3, and ultimately this will lead to senescence [13]. At the same time, PPP1CA will bind AKT, promoting its 






Figure 5. Model for the action of phosphoprotein phosphatase 1 isoforms α and γ (PPP1CA and 
PPP1CC, respectively) on the v-Akt murine thymoma viral oncogene (AKT) and mitogen-activated 
protein kinase (MAPK) signaling pathways. Phosphoprotein phosphatase 1 isoforms, when inhibit by 
cantharidin (CT), promote the activation of both pathways. However, prodigiosin (PG) may be able to 
displace CT due its higher affinity, taking PPP1CC to degradation. To compensate, PPP1CA levels 
rise, thus dephosphorylating AKT and, consequently, overcoming the inhibition of Raf and promoting 
senescence and apoptosis.                                                                
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In conclusion, we proposed a PPP1C isoform-specific dephosphorylation of AKT and MAPK, which could be 
modulated by PG, hence determining melanoma cells survival and disease progression. 
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AKT: v-Akt murine thymoma viral oncogene;  
Bcl-2: B-cell lymphoma 2;  
BRAC1: breast cancer 1 early onset;  
B-RAF: v-raf murine sarcoma viral oncogene homolog B;  
CT: cantharidin;  
ER: endoplasmic reticulum;  
GADD34: growth arrest and DNA damage-inducible protein 34;  
GSK3β: glycogen synthase kinase-3 beta;  
HDAC: histone deacetylase;  
MAPK: mitogen-activated protein kinase;  
mTOR: mammalian target of rapamycin; 
mTORC: mTOR complex;  
NAG-1: nonsteroidal anti-inflammatory drug-activated gene; 
OBX: obatoclax;  
PARP: poly ADP ribose polymerase;  
PI3K: phosphoinositide 3-kinase;  
PIP: PPP1-interacting protein;  
PG: prodigiosin;  
PPP1: phosphoprotein phosphatase 1;  
PPP1C: phosphoprotein phosphatase 1 catalytic subunit;  
PPP1CA: phosphoprotein phosphatase 1 isoform α;  
PPP1CC: phosphoprotein phosphatase 1 isoform γ;  
SPR: surface plasmon resonance;  
TSA: trichostatin A. 
 
